'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis
Cannacord Genuity Bullish On Zynerba Ahead Of CBD Gel Trial Data
Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus
Canaccord Upgrades Biogen On Deal Opportunities, Alzheimer's Pipeline